These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 8483021)

  • 21. Comparative study of the effects of lacidipine and enalapril on the left ventricular cardiomyocyte remodeling in spontaneously hypertensive rats.
    Cagalinec M; Kyselovic J; Blaskova E; Bacharova L; Chorvat D; Chorvatova A
    J Cardiovasc Pharmacol; 2006 Apr; 47(4):561-70. PubMed ID: 16680070
    [TBL] [Abstract][Full Text] [Related]  

  • 22. In vitro effects of nifedipine, nisoldipine, and lacidipine on rat isolated coronary small arteries.
    Pfaffendorf M; Mathy MJ; van Zwieten PA
    J Cardiovasc Pharmacol; 1993 Mar; 21(3):496-502. PubMed ID: 7681514
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Lacidipine improves endothelial repair capacity of endothelial progenitor cells from patients with essential hypertension.
    Liu X; Zhang GX; Zhang XY; Xia WH; Yang Z; Su C; Qiu YX; Xu SY; Zhan H; Tao J
    Int J Cardiol; 2013 Oct; 168(4):3317-26. PubMed ID: 23642821
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
    Zanchetti A; Bond MG; Hennig M; Neiss A; Mancia G; Dal Palù C; Hansson L; Magnani B; Rahn KH; Reid JL; Rodicio J; Safar M; Eckes L; Rizzini P;
    Circulation; 2002 Nov; 106(19):2422-7. PubMed ID: 12417537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of a third generation calcium antagonist in the management of hypertension.
    Epstein M
    Drugs; 1999; 57 Suppl 1():1-10. PubMed ID: 10529076
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Additive hypotensive effect of a dihydropyridine calcium antagonist to that produced by a thiazide diuretic: a double-blind placebo-controlled crossover trial with ambulatory blood pressure monitoring.
    Stergiou GS; Malakos JS; Achimastos AD; Mountokalakis TD
    J Cardiovasc Pharmacol; 1997 Mar; 29(3):412-6. PubMed ID: 9125681
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Pharmacological activity of the new calcium antagonist, lacidipine, on isolated preparations.
    Raddino R; Metra M; Nodari S; Pelá G; Fappani A; Dei Cas L
    Gen Pharmacol; 1996 Oct; 27(7):1255-9. PubMed ID: 8981077
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Are there differences in the renal effects of calcium antagonists?
    Leonetti G; Rappelli A
    J Hypertens Suppl; 1993 Mar; 11(1):S45-8. PubMed ID: 8483022
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Action of the calcium channel blocker lacidipine on cardiac hypertrophy and endothelin-1 gene expression in stroke-prone hypertensive rats.
    Feron O; Salomone S; Godfraind T
    Br J Pharmacol; 1996 Jun; 118(3):659-64. PubMed ID: 8762091
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Cardiac electrophysiologic effects of a new calcium antagonist, lacidipine.
    Cerbai E; DeBonfioli Cavalcabó P; Masini I; Visentin S; Giotti A; Mugelli A
    J Cardiovasc Pharmacol; 1990 Apr; 15(4):604-9. PubMed ID: 1691391
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Differences between calcium antagonists: duration of action and trough to peak ratio.
    Meredith PA; Reid JL
    J Hypertens Suppl; 1993 Mar; 11(1):S21-6. PubMed ID: 8483017
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vascular-selective effect of lercanidipine and other 1,4-dihydropyridines in isolated rabbit tissues.
    Angelico P; Guarneri L; Leonardi A; Testa R
    J Pharm Pharmacol; 1999 Jun; 51(6):709-14. PubMed ID: 10454048
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Calcium blocker lacidipine and carotid arteriolar vasodilation in healthy volunteers.
    Safar M; Bons J; Georges D; Cournot A; Duchier J
    Clin Pharmacol Ther; 1989 Jul; 46(1):94-8. PubMed ID: 2663319
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Coronary artery vasomotion and post-stenotic coronary artery blood flow after intracoronary lacidipine in patients with ischaemic heart disease: a pilot study.
    Vassanelli C; Menegatti G; Marini A; Beltrame F; Molinari J; Cemin R
    Drugs; 1999; 57 Suppl 1():19-26. PubMed ID: 10529079
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Safety of the calcium antagonist lacidipine evaluated from a phase III-IV trial database.
    Lindholm LH; Tcherdakoff P; Zanchetti A
    J Hypertens Suppl; 1996 Sep; 14(2):S15-20. PubMed ID: 8934373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Preclinical study of the action of a calcium channel blocker during salt load].
    Godfraind T; Salomone S; Morel N; Ghisdal P
    Bull Acad Natl Med; 1997 Feb; 181(2):289-98; discussion 299-300. PubMed ID: 9235228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lacidipine--a once-daily calcium antagonist for hypertension.
    Drug Ther Bull; 1994 Aug; 32(8):60-1. PubMed ID: 7635037
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Lacidipine reduces high blood pressure and the target organ damage induced by high fructose diet in rats.
    Cosenzi A; Bernobich E; Plazzotta N; Seculin P; Odoni G; Bellini G
    J Hypertens; 1999 Jul; 17(7):965-71. PubMed ID: 10419070
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Organ specificity of antihypertensive therapy on ocular albumin vascular clearance and albuminuria in the hypertensive diabetic rat.
    Gin T; Joon TL; Panagiotopoulos S; Cooper M; Taylor H; Jerums G
    Invest Ophthalmol Vis Sci; 1996 Feb; 37(2):281-9. PubMed ID: 8603832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Third generation of calcium antagonists: focus on lacidipine].
    Sidorenko BA; Stetsenko TM; Preobrazhenskiĭ DV; Savchenko MV; Soplevenko AV; Shabaeva EN
    Kardiologiia; 2002; 42(12):81-90. PubMed ID: 12494025
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.